Spectrum, Questcor, and Overhanging Risks (SPPI)

Spectrum, Questcor, and Overhanging Risks

Spectrum Pharmaceuticals (Nasdaq: SPPI ) recently announced approval from the Food and Drug Administration for a new manufacturing facility for its top-selling drug, Fusilev. While the news is a positive from a risk-management perspective, it does little to address the large cloud looming over the stock. Fusilev's success is largely attributable to supply shortages of a generic drug Leucovorin, used as part of typical chemotherapy treatments for colorectal cancer. As Brenton Flynn explains in the following video, as long as those supply shortages remain, investors can't truly know whether Fusilev will stand on its own or fall to the competition.

The Fusilev overhang has similarities to Questcor Pharmaceuticals' (Nasdaq: QCOR ) recent dilemma. Insurance reimbursement and government investigation concerns have caused considerable investor doubts around the stock. While both Spectrum and Questcor appear cheap using traditional valuation metrics, these risks will are likely to continue.

The pharmaceutical space is full of double-edged stories of huge growth potential and huge risk. Questcor is one of those stories. We highlight the high-profile issues facing the company inside our brand new premium research report on Questcor. In it, you'll learn about the key opportunities and threats facing the company, as well as multiple reasons to buy and sell the stock. We're providing a full year of analyst updates as key news hits, so make sure to claim a copy today by clicking here now.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Report this Comment On November 27, 2012, at 2:42 PM, Emperor2 wrote:

This is another report by someone that is totally clueless about Fusilev. This BS story about Fusilev sales drying up is a LIE. Look at Europe and Japan. Generic Leucovorin is not in short supply in Europe or Japan nor has it been in short supply. Yet sales of Fusilev by Pfizer and Sanofi-Aventis in Europe and Takeda in Japan continue to go up. Why will sales in the US go off the cliff when Leucovorin is in adequate supply whereas sales in Europe and Japan have not done so? Are doctor's in Europe and Japan stupid? Are they so much dumber than doctor's in the US? This LIE about what will happen to sales of Fusilev once Leucovorin is in adequate supply has been told long enough and loud enough and by enough people that it has become accepted as fact. But looking at the history in Europe and Japan shows that it is still a LIE. Ain't gonna happen. (Unless, of course, the doctor's in Europe and Japan really are dumber than doctor's in the US, but I doubt that.)
Report this Comment On November 27, 2012, at 4:37 PM, phxmike wrote:

Again, I have to wonder why anyone would make an analysis that leaves out so many significant facts about this stock.
1- Generic Leucovorin is chemically different
from Fusilev (Levoleucovorin) and has its own
J code for insurance billing
2- The sales have continued to climb in Europe
(Where generic Leuco exists) and the US where
generic supply has been growning
3- Spectrum has locked in many physicians on
long term supply contracts
4- The "Shelf Registration" renews one that was
put in place 3 years ago, AND WAS NEVER
USED. There is NO reason to expect they
will use it this time. Many companies do this
it's just good business to have options moving
forward. With literally hundreds of milliions in
free cash, HOW could any analyst imply this
shelf registration is an issue?
Just my opinion, do your own due diligence....seems like the analyst could have done more of his own.....
Report this Comment On November 30, 2012, at 11:02 AM, realist53 wrote:

I keep hoping to see real news/insight from articles posted here. But reality is that MF, SA, Street, etc have all become tools for the organized Market Manipulators. At least this one shows some honesty by headlining the word "fool".

updated 2 days ago Sponsored by:
	DOW	15,354.40	121.18	0.80%
	S&P 500	1,667.47	17.00	1.03%
	NASD	3,498.97	33.73	0.97%

SPPI	$8.14		+0.06	+0.74%
Spectrum Pharmaceu…		CAPS Rating:

TEVA	$40.23		+0.27	+0.68%
Teva Pharmaceutica…		CAPS Rating:

QCOR	$37.34		+0.48	+1.30%
Questcor Pharmaceu…		CAPS Rating:

My Watchlist

2

Spectrum, Questcor, and Overhanging Risks

Comments from our Foolish Readers

Report this Comment On November 27, 2012, at 2:42 PM, Emperor2 wrote:

Report this Comment On November 27, 2012, at 4:37 PM, phxmike wrote:

Report this Comment On November 30, 2012, at 11:02 AM, realist53 wrote:

Add your comment.

Compare Brokers

Report This Comment

Sending report...

Today's Market

Create My Watchlist

You don't seem to be following any stocks yet!

Most Popular Articles

Related Tickers